Iceland· IS-EU/1/16/1157/001-002 & 005
Suliqua
A insulin glargine and lixisenatide product containing insulinum glarginum inn,lixisenatidum inn,lixisenatidum inn, registered in Iceland by Sanofi Winthrop Industrie. The same ATC class is registered in 10 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Insulin glargine and lixisenatide is registered in 10 of 19 countries.
Countries holding a registration under ATC A10AE54 (insulin glargine and lixisenatide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Insulin glargine and lixisenatide · ATC A10AE54
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Insulinum glarginum INN,Lixisenatidum INN,Lixisenatidum INN
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Iceland (IS)
- ATC code
- A10AE54
- ATC class
- Insulin glargine and lixisenatide
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin glargine and lixisenatide in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSULIQUASanofi Winthrop Industrie, Gentilly
- PolandSuliquaSanofi Winthrop Industrie
- SwedenSuliqua 100 enheter/ml+33 mikrogram/ml Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- SpainSULIQUA 100 UNIDADES/ML + 33 MICROGRAMOS/ML SOLUCION INYECTABLE EN PLUMA PRECARGADASanofi Winthrop Industrie
- FinlandSuliquaSanofi Winthrop Industrie
- United KingdomSuliqua 100units/ml / 33micrograms/ml solution for injection 3ml pre-filled SoloStar pensSanofi
- IrelandSuliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled penSanofi-Aventis Groupe
- SwitzerlandSuliqua 100/33, solution injectableSanofi-Aventis (Suisse) SA
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Suliqua
- Norway · Suliqua
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5990401f-0f89-41be-a4e4-ccbb9a33d6ad GET /v1/drugs/5990401f-0f89-41be-a4e4-ccbb9a33d6ad?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltum lyfjapenna",
"source": "lyfjastofnun",
"atc_raw": "A10AE54",
"marketed": false,
"strength": "100 ein./ml + 50 míkróg/ml",
"ma_number": "EU/1/16/1157/001-002 & 005",
"substance": "Insulinum glarginum INN,Lixisenatidum INN,Lixisenatidum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "42746"
}See everything about insulin glargine and lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.